Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid LeukemiaJustin Grenet, Pinkal Desai, Madelyn Burkart et al.|Blood|2021Cited by 20